deltatrials
Terminated NA INTERVENTIONAL 2-arm NCT05504785

DexCom Hospital Study-CGM Directed Insulin Delivery

Sponsor: DexCom, Inc.

Conditions Hip Osteoarthritis Knee Osteoarthritis Type 2 Diabetes
Interventions DexCom G6 continuous glucose monitor
Updated 3 times since 2022 Last updated: Aug 15, 2022 Started: Aug 1, 2020 Primary completion: Aug 1, 2022 Completion: Aug 1, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Hip/knee arthroplasty patients are now discharged from hospital within 12 to 24 hours after COVID. patients no longer visited the pre-admission testing center after COVID so unable to insert glucose sensors pre-op.

Other terminated trials from DexCom, Inc.

More terminations from DexCom, Inc.

Other Hip Osteoarthritis trials with similar outcome

Browse all Hip Osteoarthritis trials

A NA clinical study on Hip Osteoarthritis and Knee Osteoarthritis, this trial is terminated or withdrawn. The trial is conducted by DexCom, Inc. and has accumulated 3 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

3 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated NA

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated NA

  3. Sep 2022 — Jul 2024 [monthly]

    Terminated NA

    First recorded

Aug 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • DexCom, Inc.
  • Thomas Jefferson University
Data source: Thomas Jefferson University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations